NCT02612948View on ClinicalTrials.gov

Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Psychomotor Agitation
Interventions
DRUG

Quetiapine

escalating dose to prevent delerium.

Trial Locations (1)

37922

University of Tennessee Medical Center, Knoxville

All Listed Sponsors
lead

University of Tennessee Graduate School of Medicine

OTHER

NCT02612948 - Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients | Biotech Hunter | Biotech Hunter